Generics Top 5 Emerging Markets Industry Guide 2017-2021

  • ID: 4472164
  • Report
  • 124 pages
  • MarketLine
1 of 3
Generics Top 5 Emerging Markets Industry Guide 2017-2021

Summary

The Emerging 5 Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis

Essential resource for top-line data and analysis covering the emerging five generics market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.

Key Highlights
  • These countries contributed $80,985.8 million to the global generics industry in 2016, with a compound annual growth rate (CAGR) of 13.8% between 2007 and 2011. The top 5 emerging countries are expected to reach a value of $1,27,209.2 million in 2021, with a CAGR of 9.5% over the 2016-21 period.
  • Within the generics industry, China is the leading country among the top 5 emerging nations, with market revenues of $57,010.8 million in 2016. This was followed by India and Mexico with a value of $12,654.0 and $5,430.1 million, respectively.
  • China is expected to lead the generics industry in the top five emerging nations, with a value of $87,161.6 million in 2021, followed by India and Mexico with expected values of $18,196.7 and $10,769.6 million, respectively.
Scope
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging five generics market
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging five generics market
  • Leading company profiles reveal details of key generics market players’ emerging five operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the emerging five generics market with five year forecasts by both value and volume
  • Compares data from Brazil, China, India, Mexico and South Africa, alongside individual chapters on each country
Reasons to buy
  • What was the size of the emerging five generics market by value in 2016?
  • What will be the size of the emerging five generics market in 2021?
  • What factors are affecting the strength of competition in the emerging five generics market?
  • How has the market performed over the last five years?
  • How large is the emerging five generics market in relation to its regional counterparts?
READ MORE
Note: Product cover images may vary from those shown
2 of 3
Introduction
What is this report about?
Who is the target reader?
How to use this report
Definitions
Top 5 Emerging Countries Generics
Industry Outlook
Generics in South Africa
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Brazil
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in China
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in India
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Mexico
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Company Profiles
Leading Companies
Appendix
Methodology
About the Author

List of Tables
Table 1: Top 5 emerging countries generics industry, revenue ($m), 2012-21
Table 2: Top 5 emerging countries generics industry, revenue ($m), 2012-16
Table 3: Top 5 emerging countries generics industry forecast, revenue ($m), 2016-21
Table 4: South Africa generics market value: $ million, 2012-16
Table 5: South Africa generics market volume: % of total pharma volume, 2012-16
Table 6: South Africa generics market geography segmentation: $ million, 2016
Table 7: South Africa generics market value forecast: $ million, 2016-21
Table 8: South Africa generics market volume forecast: % of total pharma volume, 2016-21
Table 61: South Africa size of population (million), 2012-16
Table 62: South Africa gdp (constant 2005 prices, $ billion), 2012-16
Table 63: South Africa gdp (current prices, $ billion), 2012-16
Table 64: South Africa inflation, 2012-16
Table 65: South Africa consumer price index (absolute), 2012-16
Table 66: South Africa exchange rate, 2012-16
Table 9: Brazil generics market value: $ million, 2012-16
Table 10: Brazil generics market volume: % of total pharma volume, 2012-16
Table 11: Brazil generics market geography segmentation: $ million, 2016
Table 12: Brazil generics market value forecast: $ million, 2016-21
Table 13: Brazil generics market volume forecast: % of total pharma volume, 2016-21
Table 14: Brazil size of population (million), 2012-16
Table 15: Brazil gdp (constant 2005 prices, $ billion), 2012-16
Table 16: Brazil gdp (current prices, $ billion), 2012-16
Table 17: Brazil inflation, 2012-16
Table 18: Brazil consumer price index (absolute), 2012-16
Table 19: Brazil exchange rate, 2012-16
Table 20: China generics market value: $ billion, 2012-16
Table 21: China generics market volume: % of total pharma volume, 2012-16
Table 22: China generics market geography segmentation: $ billion, 2016
Table 23: China generics market value forecast: $ billion, 2016-21
Table 24: China generics market volume forecast: % of total pharma volume, 2016-21
Table 25: China size of population (million), 2012-16
Table 26: China gdp (constant 2005 prices, $ billion), 2012-16
Table 27: China gdp (current prices, $ billion), 2012-16
Table 28: China inflation, 2012-16
Table 29: China consumer price index (absolute), 2012-16
Table 30: China exchange rate, 2012-16
Table 31: India generics market value: $ million, 2012-16
Table 32: India generics market volume: % of total pharma volume, 2012-16
Table 33: India generics market geography segmentation: $ million, 2016
Table 34: India generics market value forecast: $ million, 2016-21
Table 35: India generics market volume forecast: % of total pharma volume, 2016-21
Table 36: India size of population (million), 2012-16
Table 37: India gdp (constant 2005 prices, $ billion), 2012-16
Table 38: India gdp (current prices, $ billion), 2012-16
Table 39: India inflation, 2012-16
Table 40: India consumer price index (absolute), 2012-16
Table 41: India exchange rate, 2012-16
Table 42: Mexico generics market value: $ million, 2012-16
Table 43: Mexico generics market volume: % of total pharma volume, 2012-16
Table 44: Mexico generics market geography segmentation: $ million, 2016
Table 45: Mexico generics market value forecast: $ million, 2016-21
Table 46: Mexico generics market volume forecast: % of total pharma volume, 2016-21
Table 47: Mexico size of population (million), 2012-16
Table 48: Mexico gdp (constant 2005 prices, $ billion), 2012-16
Table 49: Mexico gdp (current prices, $ billion), 2012-16
Table 50: Mexico inflation, 2012-16
Table 51: Mexico consumer price index (absolute), 2012-16
Table 52: Mexico exchange rate, 2012-16
Table 53: Adcock Ingram Holdings Ltd: key facts
Table 54: Adcock Ingram Holdings Ltd: key financials ($)
Table 55: Adcock Ingram Holdings Ltd: key financials (ZAR)
Table 56: Adcock Ingram Holdings Ltd: key financial ratios
Table 57: Aspen Pharmacare Holdings Ltd: key facts
Table 58: Aspen Pharmacare Holdings Ltd: key financials ($)
Table 59: Aspen Pharmacare Holdings Ltd: key financials (ZAR)
Table 60: Aspen Pharmacare Holdings Ltd: key financial ratios
Table 67: Ache Laboratorios Farmaceuticos SA: key facts
Table 68: EMS SA: key facts
Table 69: Sanofi SA: key facts
Table 70: Sanofi SA: key financials ($)
Table 71: Sanofi SA: key financials (€)
Table 72: Sanofi SA: key financial ratios
Table 73: Eurofarma Laboratorios SA: key facts
Table 74: China Grand Pharmaceutical and Healthcare Holdings Limited: key facts
Table 75: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials ($)
Table 76: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials (CNY)
Table 77: China Grand Pharmaceutical and Healthcare Holdings Limited: key financial ratios
Table 78: Mylan N.V.: key facts
Table 79: Mylan N.V.: key financials ($)
Table 80: Mylan N.V.: key financial ratios
Table 81: Aurobindo Pharma Limited: key facts
Table 82: Aurobindo Pharma Limited: key financials ($)
Table 83: Aurobindo Pharma Limited: key financials (A$)
Table 84: Aurobindo Pharma Limited: key financial ratios
Table 85: Cipla Limited: key facts
Table 86: Cipla Limited: key financials ($)
Table 87: Cipla Limited: key financials (Rs.)
Table 88: Cipla Limited: key financial ratios
Table 89: Lupin Ltd: key facts
Table 90: Lupin Ltd: key financials ($)
Table 91: Lupin Ltd: key financials (Rs.)
Table 92: Lupin Ltd: key financial ratios
Table 93: Sun Pharmaceutical Industries Ltd: key facts
Table 94: Sun Pharmaceutical Industries Ltd: key financials ($)
Table 95: Sun Pharmaceutical Industries Ltd: key financials (Rs.)
Table 96: Sun Pharmaceutical Industries Ltd: key financial ratios
Table 97: Apotex, Inc.: key facts
Table 98: Novartis AG: key facts
Table 99: Novartis AG: key financials ($)
Table 100: Novartis AG: key financial ratios
Table 101: Teva Pharmaceutical Industries Limited: key facts
Table 102: Teva Pharmaceutical Industries Limited: key financials ($)
Table 103: Teva Pharmaceutical Industries Limited: key financial ratios

List of Figures
Figure 1: Top 5 emerging countries generics industry, revenue ($m), 2012-21
Figure 2: Top 5 emerging countries generics industry, revenue ($m), 2012-16
Figure 3: Top 5 emerging countries generics industry forecast, revenue ($m), 2016-21
Figure 4: South Africa generics market value: $ million, 2012-16
Figure 5: South Africa generics market volume: % of total pharma volume, 2012-16
Figure 6: South Africa generics market geography segmentation: % share, by value, 2016
Figure 7: South Africa generics market value forecast: $ million, 2016-21
Figure 8: South Africa generics market volume forecast: % of total pharma volume, 2016-21
Figure 9: Forces driving competition in the generics market in South Africa, 2016
Figure 10: Drivers of buyer power in the generics market in South Africa, 2016
Figure 11: Drivers of supplier power in the generics market in South Africa, 2016
Figure 12: Factors influencing the likelihood of new entrants in the generics market in South Africa, 2016
Figure 13: Factors influencing the threat of substitutes in the generics market in South Africa, 2016
Figure 14: Drivers of degree of rivalry in the generics market in South Africa, 2016
Figure 15: Brazil generics market value: $ million, 2012-16
Figure 16: Brazil generics market volume: % of total pharma volume, 2012-16
Figure 17: Brazil generics market geography segmentation: % share, by value, 2016
Figure 18: Brazil generics market value forecast: $ million, 2016-21
Figure 19: Brazil generics market volume forecast: % of total pharma volume, 2016-21
Figure 20: Forces driving competition in the generics market in Brazil, 2016
Figure 21: Drivers of buyer power in the generics market in Brazil, 2016
Figure 22: Drivers of supplier power in the generics market in Brazil, 2016
Figure 23: Factors influencing the likelihood of new entrants in the generics market in Brazil, 2016
Figure 24: Factors influencing the threat of substitutes in the generics market in Brazil, 2016
Figure 25: Drivers of degree of rivalry in the generics market in Brazil, 2016
Figure 26: China generics market value: $ billion, 2012-16
Figure 27: China generics market volume: % of total pharma volume, 2012-16
Figure 28: China generics market geography segmentation: % share, by value, 2016
Figure 29: China generics market value forecast: $ billion, 2016-21
Figure 30: China generics market volume forecast: % of total pharma volume, 2016-21
Figure 31: Forces driving competition in the generics market in China, 2016
Figure 32: Drivers of buyer power in the generics market in China, 2016
Figure 33: Drivers of supplier power in the generics market in China, 2016
Figure 34: Factors influencing the likelihood of new entrants in the generics market in China, 2016
Figure 35: Factors influencing the threat of substitutes in the generics market in China, 2016
Figure 36: Drivers of degree of rivalry in the generics market in China, 2016
Figure 37: India generics market value: $ million, 2012-16
Figure 38: India generics market volume: % of total pharma volume, 2012-16
Figure 39: India generics market geography segmentation: % share, by value, 2016
Figure 40: India generics market value forecast: $ million, 2016-21
Figure 41: India generics market volume forecast: % of total pharma volume, 2016-21
Figure 42: Forces driving competition in the generics market in India, 2016
Figure 43: Drivers of buyer power in the generics market in India, 2016
Figure 44: Drivers of supplier power in the generics market in India, 2016
Figure 45: Factors influencing the likelihood of new entrants in the generics market in India, 2016
Figure 46: Factors influencing the threat of substitutes in the generics market in India, 2016
Figure 47: Drivers of degree of rivalry in the generics market in India, 2016
Figure 48: Mexico generics market value: $ million, 2012-16
Figure 49: Mexico generics market volume: % of total pharma volume, 2012-16
Figure 50: Mexico generics market geography segmentation: % share, by value, 2016
Figure 51: Mexico generics market value forecast: $ million, 2016-21
Figure 52: Mexico generics market volume forecast: % of total pharma volume, 2016-21
Figure 53: Forces driving competition in the generics market in Mexico, 2016
Figure 54: Drivers of buyer power in the generics market in Mexico, 2016
Figure 55: Drivers of supplier power in the generics market in Mexico, 2016
Figure 56: Factors influencing the likelihood of new entrants in the generics market in Mexico, 2016
Figure 57: Factors influencing the threat of substitutes in the generics market in Mexico, 2016
Figure 58: Drivers of degree of rivalry in the generics market in Mexico, 2016
Figure 59: Adcock Ingram Holdings Ltd: revenues & profitability
Figure 60: Adcock Ingram Holdings Ltd: assets & liabilities
Figure 61: Aspen Pharmacare Holdings Ltd: revenues & profitability
Figure 62: Aspen Pharmacare Holdings Ltd: assets & liabilities
Figure 63: Sanofi SA: revenues & profitability
Figure 64: Sanofi SA: assets & liabilities
Figure 65: China Grand Pharmaceutical and Healthcare Holdings Limited: revenues & profitability
Figure 66: China Grand Pharmaceutical and Healthcare Holdings Limited: assets & liabilities
Figure 67: Mylan N.V.: revenues & profitability
Figure 68: Mylan N.V.: assets & liabilities
Figure 69: Aurobindo Pharma Limited: revenues & profitability
Figure 70: Aurobindo Pharma Limited: assets & liabilities
Figure 71: Cipla Limited: revenues & profitability
Figure 72: Cipla Limited: assets & liabilities
Figure 73: Lupin Ltd: revenues & profitability
Figure 74: Lupin Ltd: assets & liabilities
Figure 75: Sun Pharmaceutical Industries Ltd: revenues & profitability
Figure 76: Sun Pharmaceutical Industries Ltd: assets & liabilities
Figure 77: Novartis AG: revenues & profitability
Figure 78: Novartis AG: assets & liabilities
Figure 79: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 80: Teva Pharmaceutical Industries Limited: assets & liabilities
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll